Investors Purchase Large Volume of Microbot Medical Call Options (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) was the target of some unusual options trading activity on Monday. Investors acquired 2,704 call options on the company. This is an increase of approximately 122% compared to the average daily volume of 1,216 call options.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Microbot Medical in a research report on Thursday, April 10th.

Institutional Trading of Microbot Medical

Institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new position in Microbot Medical during the 4th quarter valued at about $118,000. Goldman Sachs Group Inc. acquired a new stake in shares of Microbot Medical during the 1st quarter worth approximately $57,000. Virtu Financial LLC acquired a new stake in shares of Microbot Medical during the 1st quarter worth approximately $42,000. Finally, Geode Capital Management LLC boosted its stake in Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 10,442 shares during the last quarter. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Stock Performance

Shares of NASDAQ:MBOT opened at $2.49 on Tuesday. The company has a market cap of $90.58 million, a PE ratio of -3.11 and a beta of 1.14. Microbot Medical has a 52 week low of $0.82 and a 52 week high of $3.38. The firm has a 50 day simple moving average of $2.38 and a 200 day simple moving average of $1.83.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.07. On average, equities analysts predict that Microbot Medical will post -0.71 earnings per share for the current year.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.